ANI Pharmaceuticals

Novitium Pharma is a pharmaceutical company based in New Jersey that focuses on the development, manufacturing, and distribution of niche generic products. The company offers a diverse commercial product portfolio that includes tablets, oral solutions, capsules, liquids, injections, powders, and gels, catering to the needs of pharmacists, patients, and communities. Novitium is committed to producing affordable, high-quality medications to ensure accessibility for those requiring pharmaceutical care. Through its ongoing investments, the company aims to address various therapeutic categories and dosage forms, fulfilling the evolving needs of the healthcare market.

WellSpring Pharma Services Inc. is a pharmaceutical manufacturer based in Oakville, Canada, founded in 2001. The company specializes in contract manufacturing services, offering a comprehensive range of non-sterile finished dosage forms, including solids, semisolids, and oral liquids and suspensions. WellSpring is committed to quality, precision, and continuous improvement, adhering to stringent current Good Manufacturing Practice (cGMP) standards. The organization maintains an excellent audit history with regulatory authorities such as the US Food and Drug Administration and Health Canada. In August 2018, WellSpring Pharma Services was acquired by ANI Pharmaceuticals Canada Inc.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.